ASTCT, CIBMTR, and EBMT clinical practice recommendations for transplant and cellular therapies in mantle cell lymphoma
(2021) In Bone Marrow Transplantation 56(12). p.2911-2921- Abstract
Autologous (auto-) or allogeneic (allo-) hematopoietic cell transplantation (HCT) are accepted treatment modalities for mantle cell lymphoma (MCL). Recently, chimeric antigen receptor (CAR) T-cell therapy received approval for MCL; however, its exact place and sequence in relation to HCT is unclear. The ASTCT, CIBMTR, and the EBMT, jointly convened an expert panel to formulate consensus recommendations for role, timing, and sequencing of auto-, allo-HCT, and CAR T-cell therapy for patients with newly diagnosed and relapsed/refractory (R/R) MCL. The RAND-modified Delphi method was used to generate consensus statements. Seventeen consensus statements were generated; in the first-line setting auto-HCT consolidation represents... (More)
Autologous (auto-) or allogeneic (allo-) hematopoietic cell transplantation (HCT) are accepted treatment modalities for mantle cell lymphoma (MCL). Recently, chimeric antigen receptor (CAR) T-cell therapy received approval for MCL; however, its exact place and sequence in relation to HCT is unclear. The ASTCT, CIBMTR, and the EBMT, jointly convened an expert panel to formulate consensus recommendations for role, timing, and sequencing of auto-, allo-HCT, and CAR T-cell therapy for patients with newly diagnosed and relapsed/refractory (R/R) MCL. The RAND-modified Delphi method was used to generate consensus statements. Seventeen consensus statements were generated; in the first-line setting auto-HCT consolidation represents standard-of-care in eligible patients, whereas there is no clear role of allo-HCT or CAR T-cell therapy, outside of a clinical trial. In the R/R setting, the preferential option is CAR T-cell therapy especially in MCL failing or intolerant to at least one Bruton’s tyrosine kinase inhibitor, while allo-HCT is recommended if CAR T-cell therapy has failed or is not feasible. In the absence of contemporary evidence-based data, the panel found RAND-modified Delphi methodology effective in providing a formal framework for developing consensus recommendations for the timing and sequence of cellular therapies for MCL.
(Less)
- author
- organization
- publishing date
- 2021
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Bone Marrow Transplantation
- volume
- 56
- issue
- 12
- pages
- 2911 - 2921
- publisher
- Nature Publishing Group
- external identifiers
-
- scopus:85113212083
- pmid:34413469
- ISSN
- 0268-3369
- DOI
- 10.1038/s41409-021-01288-9
- language
- English
- LU publication?
- yes
- id
- 879ee387-cb8c-48f6-a573-622a1b2fc594
- date added to LUP
- 2021-09-06 14:45:03
- date last changed
- 2024-08-10 20:33:57
@article{879ee387-cb8c-48f6-a573-622a1b2fc594, abstract = {{<p>Autologous (auto-) or allogeneic (allo-) hematopoietic cell transplantation (HCT) are accepted treatment modalities for mantle cell lymphoma (MCL). Recently, chimeric antigen receptor (CAR) T-cell therapy received approval for MCL; however, its exact place and sequence in relation to HCT is unclear. The ASTCT, CIBMTR, and the EBMT, jointly convened an expert panel to formulate consensus recommendations for role, timing, and sequencing of auto-, allo-HCT, and CAR T-cell therapy for patients with newly diagnosed and relapsed/refractory (R/R) MCL. The RAND-modified Delphi method was used to generate consensus statements. Seventeen consensus statements were generated; in the first-line setting auto-HCT consolidation represents standard-of-care in eligible patients, whereas there is no clear role of allo-HCT or CAR T-cell therapy, outside of a clinical trial. In the R/R setting, the preferential option is CAR T-cell therapy especially in MCL failing or intolerant to at least one Bruton’s tyrosine kinase inhibitor, while allo-HCT is recommended if CAR T-cell therapy has failed or is not feasible. In the absence of contemporary evidence-based data, the panel found RAND-modified Delphi methodology effective in providing a formal framework for developing consensus recommendations for the timing and sequence of cellular therapies for MCL.</p>}}, author = {{Munshi, Pashna N. and Hamadani, Mehdi and Kumar, Ambuj and Dreger, Peter and Friedberg, Jonathan W. and Dreyling, Martin and Kahl, Brad and Jerkeman, Mats and Kharfan-Dabaja, Mohamed A. and Locke, Frederick L. and Shadman, Mazyar and Hill, Brian T. and Ahmed, Sairah and Herrera, Alex F. and Sauter, Craig S. and Bachanova, Veronika and Ghosh, Nilanjan and Lunning, Matthew and Kenkre, Vaishalee P. and Aljurf, Mahmoud and Wang, Michael and Maddocks, Kami J. and Leonard, John P. and Kamdar, Manali and Phillips, Tycel and Cashen, Amanda F. and Inwards, David J. and Sureda, Anna and Cohen, Jonathon B. and Smith, Sonali M. and Carlo-Stella, Carmello and Savani, Bipin and Robinson, Stephen P. and Fenske, Timothy S.}}, issn = {{0268-3369}}, language = {{eng}}, number = {{12}}, pages = {{2911--2921}}, publisher = {{Nature Publishing Group}}, series = {{Bone Marrow Transplantation}}, title = {{ASTCT, CIBMTR, and EBMT clinical practice recommendations for transplant and cellular therapies in mantle cell lymphoma}}, url = {{http://dx.doi.org/10.1038/s41409-021-01288-9}}, doi = {{10.1038/s41409-021-01288-9}}, volume = {{56}}, year = {{2021}}, }